Intralesional Purified Protein Derivative of Tuberculin Versus Intralesional Mycobacterium W Vaccine in Treatment of Recalcitrant Extragenital Warts | Zendy

Alpana Mohta | Zendy; SureshKumar Jain | Zendy; Rajesh Dutt Mehta | Zendy; Aakanksha Arora | Zendy

Open Access

Intralesional Purified Protein Derivative of Tuberculin Versus Intralesional Mycobacterium W Vaccine in Treatment of Recalcitrant Extragenital Warts

Author(s) -

Alpana Mohta,

SureshKumar Jain,

Rajesh Dutt Mehta,

Aakanksha Arora

Publication year - 2022

Publication title -

indian journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.395

H-Index - 36

eISSN - 1998-3611

pISSN - 0019-5154

DOI - 10.4103/ijd.ijd_521_21

Subject(s) - medicine , tuberculin , dermatology , adverse effect , erythema , vaccination , purified protein derivative , population , bcg vaccine , tuberculosis , surgery , immunology , pathology , environmental health

Of late, immunotherapy has emerged as a promising therapeutic modality for the treatment of recalcitrant and difficult to treat warts. Purified protein derivative of tuberculin (PDD) and mycobacterium w (Mw) vaccine hold promising prospects for the treatment of verruca, especially in a country like ours where a majority of the population is already sensitized to mycobacterium tuberculosis both due to disease endemicity and Bacillus Calmette-Guérin (BCG) vaccination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research